Jon E. Angell

Array ( [id] => 6096400 [patent_doc_number] => 20110003378 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-01-06 [patent_title] => 'MULTIPLE PROMOTER EXPRESSION CASSETTES FOR SIMULTANEOUS DELIVERY OF RNAi AGENTS' [patent_app_type] => utility [patent_app_number] => 12/723466 [patent_app_country] => US [patent_app_date] => 2010-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 19564 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0003/20110003378.pdf [firstpage_image] =>[orig_patent_app_number] => 12723466 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8005697 [patent_doc_number] => 08084249 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2011-12-27 [patent_title] => 'Vector' [patent_app_type] => utility [patent_app_number] => 12/714264 [patent_app_country] => US [patent_app_date] => 2010-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 12 [patent_no_of_words] => 21543 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/084/08084249.pdf [firstpage_image] =>[orig_patent_app_number] => 12714264 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6234843 [patent_doc_number] => 20100266547 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-10-21 [patent_title] => 'METHODS AND COMPOSITIONS FOR TREATMENT OF INTERFERON-RESISTANT TUMORS' [patent_app_type] => utility [patent_app_number] => 12/706625 [patent_app_country] => US [patent_app_date] => 2010-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 11599 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0266/20100266547.pdf [firstpage_image] =>[orig_patent_app_number] => 12706625 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8339702 [patent_doc_number] => 08241623 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2012-08-14 [patent_title] => 'Protease sensitivity expression system' [patent_app_type] => utility [patent_app_number] => 12/703158 [patent_app_country] => US [patent_app_date] => 2010-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 11 [patent_no_of_words] => 11223 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12703158 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10032905 [patent_doc_number] => 09074212 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-07-07 [patent_title] => 'RNAi inhibition of alpha-ENaC expression' [patent_app_type] => utility [patent_app_number] => 12/683146 [patent_app_country] => US [patent_app_date] => 2010-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 38420 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12683146 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6379903 [patent_doc_number] => 20100316615 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-12-16 [patent_title] => 'Antisense Oligonucleotides Against VR1' [patent_app_type] => utility [patent_app_number] => 12/645625 [patent_app_country] => US [patent_app_date] => 2009-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 10269 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0316/20100316615.pdf [firstpage_image] =>[orig_patent_app_number] => 12645625 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5987765 [patent_doc_number] => 20110098460 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-04-28 [patent_title] => 'SiRNA Useful to Suppress expression of eIF-5A1' [patent_app_type] => utility [patent_app_number] => 12/640148 [patent_app_country] => US [patent_app_date] => 2009-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 101 [patent_figures_cnt] => 101 [patent_no_of_words] => 33726 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0098/20110098460.pdf [firstpage_image] =>[orig_patent_app_number] => 12640148 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6231435 [patent_doc_number] => 20100184670 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-07-22 [patent_title] => 'ANTISENSE COMPOSITIONS AND METHODS FOR MODULATING CONTACT HYPERSENSITIVITY OR CONTACT DERMATITIS' [patent_app_type] => utility [patent_app_number] => 12/641159 [patent_app_country] => US [patent_app_date] => 2009-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 25687 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0184/20100184670.pdf [firstpage_image] =>[orig_patent_app_number] => 12641159 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6323056 [patent_doc_number] => 20100113761 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-05-06 [patent_title] => 'siRNA targeting beta secretase (BACE)' [patent_app_type] => utility [patent_app_number] => 12/653402 [patent_app_country] => US [patent_app_date] => 2009-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 44 [patent_no_of_words] => 34645 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0113/20100113761.pdf [firstpage_image] =>[orig_patent_app_number] => 12653402 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6583138 [patent_doc_number] => 20100291188 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-11-18 [patent_title] => 'Periostin Inhibitory Compositions for Myocardial Regeneration, Methods of Delivery, and Methods of Using Same' [patent_app_type] => utility [patent_app_number] => 12/631655 [patent_app_country] => US [patent_app_date] => 2009-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 19924 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0291/20100291188.pdf [firstpage_image] =>[orig_patent_app_number] => 12631655 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10104052 [patent_doc_number] => 09139827 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-09-22 [patent_title] => 'Polyvalent RNA-nanoparticle compositions' [patent_app_type] => utility [patent_app_number] => 12/625537 [patent_app_country] => US [patent_app_date] => 2009-11-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 15489 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12625537 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6374169 [patent_doc_number] => 20100075869 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-03-25 [patent_title] => 'siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1)' [patent_app_type] => utility [patent_app_number] => 12/590707 [patent_app_country] => US [patent_app_date] => 2009-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 44 [patent_no_of_words] => 34748 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0075/20100075869.pdf [firstpage_image] =>[orig_patent_app_number] => 12590707 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4710 [patent_doc_number] => 07816512 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2010-10-19 [patent_title] => 'siRNA targeting proto-oncogene MET' [patent_app_type] => utility [patent_app_number] => 12/590097 [patent_app_country] => US [patent_app_date] => 2009-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 43 [patent_no_of_words] => 34708 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/816/07816512.pdf [firstpage_image] =>[orig_patent_app_number] => 12590097 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9575517 [patent_doc_number] => 08765931 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-07-01 [patent_title] => 'Double-stranded oligonucleotide compound for down-regulating the expression of CASP2 gene' [patent_app_type] => utility [patent_app_number] => 13/062161 [patent_app_country] => US [patent_app_date] => 2009-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 28 [patent_no_of_words] => 53974 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13062161 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6228820 [patent_doc_number] => 20100183558 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-07-22 [patent_title] => 'SAFE LENTIVIRAL VECTORS FOR TARGETED DELIVERY OF MULTIPLE THERAPEUTIC MOLECULES' [patent_app_type] => utility [patent_app_number] => 12/581871 [patent_app_country] => US [patent_app_date] => 2009-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 51 [patent_figures_cnt] => 51 [patent_no_of_words] => 19232 [patent_no_of_claims] => 48 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0183/20100183558.pdf [firstpage_image] =>[orig_patent_app_number] => 12581871 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10876074 [patent_doc_number] => 08900858 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-12-02 [patent_title] => 'Methods and compositions relating to improved lentiviral vector production systems' [patent_app_type] => utility [patent_app_number] => 12/578346 [patent_app_country] => US [patent_app_date] => 2009-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 25085 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12578346 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6616879 [patent_doc_number] => 20100099740 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-04-22 [patent_title] => 'METHODS AND COMPOSITIONS FOR RNAI MEDIATED INHIBITION OF GENE EXPRESSION IN MAMMALS' [patent_app_type] => utility [patent_app_number] => 12/576052 [patent_app_country] => US [patent_app_date] => 2009-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 18298 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0099/20100099740.pdf [firstpage_image] =>[orig_patent_app_number] => 12576052 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7697030 [patent_doc_number] => 20110229560 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-09-22 [patent_title] => 'NLRC5 AS A TARGET FOR IMMUNE THERAPY' [patent_app_type] => utility [patent_app_number] => 13/122838 [patent_app_country] => US [patent_app_date] => 2009-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 66 [patent_figures_cnt] => 66 [patent_no_of_words] => 29767 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0229/20110229560.pdf [firstpage_image] =>[orig_patent_app_number] => 13122838 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6289712 [patent_doc_number] => 20100158867 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-06-24 [patent_title] => 'PARAMYXOVIRUS VECTOR ENCODING ANGIOGENESIS GENE AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 12/571196 [patent_app_country] => US [patent_app_date] => 2009-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 22753 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0158/20100158867.pdf [firstpage_image] =>[orig_patent_app_number] => 12571196 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10882695 [patent_doc_number] => 08907075 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-12-09 [patent_title] => 'Compositions and methods for gene silencing' [patent_app_type] => utility [patent_app_number] => 12/570389 [patent_app_country] => US [patent_app_date] => 2009-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 24417 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12570389 [rel_patent_id] =>[rel_patent_doc_number] =>)